Literature DB >> 22799314

The clinicopathological and prognostic impact of 14-3-3 protein isoforms expression in human cholangiocarcinoma by immunohistochemistry.

Qiao Wu1, Chang-Zheng Liu, Lian-Yuan Tao, Lan Yu, Wei Liu, Song-Sen Chen, Xiao-Dong He.   

Abstract

The 14-3-3 proteins are highly conserved, ubiquitous molecules involved in a variety of biologic phenomena, such as cell cycle control, and apoptosis. However, their expression in cholangiocarcinoma has not been previously characterized. In this paper, immunohistochemistry using specific anti-14-3-3 monoclonal antibodies was performed on formalin-fixed;, paraffin embedded archival tissue from 86 patients of cholangiocarcinoma. We also examined the correlation between expression and survival rate and clinicopathologic factors such as tumor location, tumor size, pathologic differentiation, lymphatic permeation, lymph node metastasis, and tumor stage. Positive 14-3-3 proteins expression was observed for 6 isoforms (β, σ, γ, θ, β, η) of these proteins in 86 patients of cholangiocarcinoma. β and σ isoform immunoreactivity was correlated with lymph node metastasis, tumor stage and patients' survival rate. In addition, δ isoform immunoreactivity showed trends with tumor location, tumor size, pathologic differentiation and tumor stage, while the θ isoform was correlated with pathologic differentiation. These results indicated that upregulated expression of some isoforms of 14-3-3 may be a common mechanism for evading apoptosis in cholangiocarcinoma, so that targeting 14-3-3 may be a novel promising strategy for the treatment of this tumor.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22799314     DOI: 10.7314/apjcp.2012.13.4.1253

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  8 in total

1.  Up-regulation of 14-3-3ζ expression in intrahepatic cholangiocarcinoma and its clinical implications.

Authors:  Chi Zhang; Li-Xin Liu; Zhao-Ru Dong; Guo-Ming Shi; Jia-Bin Cai; Peng-Fei Zhang; Ai-Wu Ke; Jing-Xian Yu; Jian Zhou; Jia Fan
Journal:  Tumour Biol       Date:  2014-11-13

Review 2.  Molecular Mechanisms Driving Cholangiocarcinoma Invasiveness: An Overview.

Authors:  Simone Brivio; Massimiliano Cadamuro; Luca Fabris; Mario Strazzabosco
Journal:  Gene Expr       Date:  2017-10-25

Review 3.  An Omics Perspective on Molecular Biomarkers for Diagnosis, Prognosis, and Therapeutics of Cholangiocarcinoma.

Authors:  Pattaya Seeree; Phorutai Pearngam; Supeecha Kumkate; Tavan Janvilisri
Journal:  Int J Genomics       Date:  2015-09-02       Impact factor: 2.326

4.  14-3-3η is a novel mediator associated with the pathogenesis of rheumatoid arthritis and joint damage.

Authors:  Walter P Maksymowych; Désirée van der Heijde; Cornelia F Allaart; Robert Landewé; Gilles Boire; Paul P Tak; Yuan Gui; Aziz Ghahary; Ruhangiz Kilani; Anthony Marotta
Journal:  Arthritis Res Ther       Date:  2014-04-21       Impact factor: 5.156

5.  Overexpression of 14-3-3σ Modulates Cholangiocarcinoma Cell Survival by PI3K/Akt Signaling.

Authors:  Qiao Wu; Hua Fan; Ren Lang; Xianliang Li; Xingmao Zhang; Shaocheng Lv; Qiang He
Journal:  Biomed Res Int       Date:  2020-06-22       Impact factor: 3.411

6.  Overexpression of 14-3-3δ Predicts Poor Prognosis in Extrahepatic Cholangiocarcinoma Patients.

Authors:  Qiao Wu; Hua Fan; Ren Lang; Xianliang Li; Xingmao Zhang; Shaocheng Lv; Qiang He
Journal:  Biomed Res Int       Date:  2020-06-19       Impact factor: 3.411

7.  Serum 14-3-3η level is associated with severity and clinical outcomes of rheumatoid arthritis, and its pretreatment level is predictive of DAS28 remission with tocilizumab.

Authors:  Shintaro Hirata; Anthony Marotta; Yuan Gui; Kentaro Hanami; Yoshiya Tanaka
Journal:  Arthritis Res Ther       Date:  2015-10-09       Impact factor: 5.156

8.  Decreased expression of 14-3-3 σ, an early event of malignant transformation of respiratory epithelium, also facilitates progression of squamous cell lung cancer.

Authors:  Nan Sun; Yongkai Wu; Bo Huang; Qian Liu; Yinan Dong; Jianqiao Ding; Yongyu Liu
Journal:  Thorac Cancer       Date:  2015-03-18       Impact factor: 3.500

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.